[Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major].
We report on the lethal course of a patient receiving low-dose, weekly docetaxel who developed acute liver failure accompanied by a Stevens-Johnson syndrome. After receiving the fifth application of his chemotherapy, the patient was admitted to hospital because of neutropenia and severe erythema. The course worsened towards an acute liver failure and an erythema multiforme major. Despite an interdisciplinary approach, the further course could not be influenced and the patient died 6 weeks after admission due the toxicity of docetaxel. This case report underlines the spectrum of toxicity of docetaxel even in the low-dose weekly schedule.
Ohlmann
C-H
CH
Klinik und Poliklinik für Urologie, Klinikum der Universität zu Köln, 50937 Köln. Carsten-Henning.Ohlmann@uk-koeln.de
Kohlmorgen
S
S
Sahi
D
D
Engelmann
U
U
Heidenreich
A
A
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D014408:Biomarkers, Tumor / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D017809:Fatal Outcome; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced / Q000175:diagnosis; D008111:Liver Function Tests; D008297:Male; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D043823:Taxoids / Q000008:administration & dosage / Q000633:toxicity*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen